rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    HIMS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Hims Is Getting into Peptides
      9h agoYahoo FinanceHIMS
      Hims & Hers launches peptide therapy specialty service
      12h agoInvesting.comHIMS
      Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy

      The telehealth company will now offer compounded forms of sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine, none of which are approved by the FDA.

      12h agoCNBCHIMS
      Floodgates open for unproven wellness drugs after US lifts peptide curbs
      15h agoFinancial TimesHIMS
      Hims & Hers Stock Fell 32% As Profit Slipped
      Nov 17Yahoo FinanceHIMS
      Hims & Hers Health (HIMS) Added FDA Approved Obesity Drugs To Its Platform
      Nov 17Yahoo FinanceHIMS
      Hims & Hers: Further Expanding Internationally

      Analyst rates Hims & Hers Health a Strong Buy: $23.8 implies roughly 20% upside toward a 15% annual return, led by international expansion.

      Nov 16Seeking AlphaHIMS
      Hims & Hers Health Stock Crashes After Earnings: Is Now the Time to Buy? | The Motley Fool

      The company generated strong growth last quarter, but its bottom line didn't look nearly as impressive.

      Nov 16The Motley FoolHIMS
      Why Is Hims Stock Crashing, and is it a Buying Opportunity? | The Motley Fool

      Revenue is increasing, but so are its operating expenses.

      Nov 14The Motley FoolHIMS
      What Hims & Hers Health Investors Missed Before The Fall
      Nov 14Yahoo FinanceHIMS
      Should Hims & Hers Stock's Drop After Earnings Worry You?
      Nov 13Yahoo FinanceHIMS
      HIMS Partners With Lilly to Offer FDA-Approved Weight-Loss Drugs
      Nov 13Yahoo FinanceHIMSLLY
      Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
      Nov 13Yahoo FinanceHIMS
      Which Dates Could Move Hims & Hers Stock Most?
      Nov 12Yahoo FinanceHIMS
      Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off
      Nov 12Yahoo FinanceHIMS
      Why GLP-1s Won't Be The Last 'Explosive' Story In Peptides

      Hims stock zoomed higher on an HHS push to legalize six peptides. It could be just the beginning of a healthcare overhaul.

      Nov 12Investor's Business DailyHIMS
      Hims & Hers: Three Big Sacrifices (NYSE:HIMS)
      Nov 11Seeking AlphaHIMS
      Hims & Hers Health: The Thesis Is Getting Shaky (Rating Downgrade) (NYSE:HIMS)

      Hims & Hers Health, Inc., is a Hold: Q3 growth excluding Eucalyptus was 26%. Click for this HIMS stock earnings update and see if it is right for you.

      Nov 11Seeking AlphaHIMS
      Hims & Hers Climbs 6% Despite Five States Joining FTC Suit; Eli Lilly Dips, Novo Nordisk Holds Steady
      Nov 11Yahoo FinanceHIMSLLYNVO
      Hims & Hers Under Fire: Five More States Join Federal Crackdown Over Alleged Privacy Violations
      Nov 11BenzingaHIMS
      Hims & Hers Q3 Earnings Miss Estimates, Gross Margin Down
      Nov 11Yahoo FinanceHIMS
      Hims & Hers Week in Review: Q3 Miss, Weak Q4 Outlook, Huberman Joins Board
      Nov 11BenzingaHIMS
      Hims & Hers Faces A ‘Transition Year’ Amid Increasing AI Investments, Says KeyBanc – Expects Lower Pricing To Weigh On FY2027-2028 Earnings Outlook
      Nov 11Yahoo FinanceHIMS
      KeyBanc Waits for a Growth Inflection at Hims & Hers

      The firm kept a Sector Weight rating, saying it wants more signs of a growth inflection

      Nov 11Yahoo FinanceHIMS
      Hims and Hers stock rating held at Sector Weight by KeyBanc
      Nov 11Investing.comHIMS
      Five US states join FTC suit against Hims & Hers over privacy practices

      By Kanishka Singh WASHINGTON, Nov 10 (Reuters) - Five US states have joined the Federal Trade Commission in a lawsuit that alleges telehealth company Hims & Hers Health engaged in deceptive and

      Nov 11Yahoo FinanceHIMS
      Hims & Hers (HIMS) Stock Price Faces Q3 Results Margin Reckoning
      Nov 11Yahoo FinanceHIMS
      HIMS Stock Faces Dual Blow From Expanded FTC Privacy Lawsuit After Selloff Driven By Q3 Subscriber Loss
      Nov 10Yahoo FinanceHIMS
      Five US states join FTC suit over alleged Hims & Hers unlawful practices By Reuters
      Nov 10Investing.comHIMS
      Five US states join FTC suit over alleged Hims & Hers unlawful practices
      Nov 10ReutersHIMS
      Hims & Hers Health: Don't Nickpick Quarterly Results (NYSE:HIMS)

      Hims & Hers Health maintains robust growth prospects despite a minor Q3'26 revenue miss, leading to a market overreaction. Read more on HIMS stock here.

      Nov 10Seeking AlphaHIMS
      HIMS Q3 Earnings Call Highlights Marketing Reset and Margin Pressure
      Nov 10Yahoo FinanceHIMS
      Why Is Hims & Hers Health (HIMS) Bringing Andrew Huberman Onto Its Board?

      Hims & Hers Health (NYSE:HIMS) has appointed neuroscientist Dr. Andrew Huberman to its Board of Directors. Dr. Huberman will also serve as a scientific advisor to Hims & Hers Health, guiding neuroscience and wellness related product thinking. He will act as a brand and marketing advisor, bringing experience from his global audience and health focused podcast to consumer outreach. Dr. Andrew Huberman joining the Hims & Hers Health board and advisory group sits against broader themes our...

      Nov 10Yahoo FinanceHIMS
      Hims & Hers Stocks Plunge 15.37% as Margin Squeeze Forces EBITDA Guidance Cut

      Revenue rose 49% to $890.4 million, but gross margin collapsed to 57% from 74% and full-year profit guidance moved lower.

      Nov 10Yahoo FinanceHIMS
      Why Is Hims & Hers Health Stock Falling Today? - Hims & Hers Health (NYSE:HIMS)
      Nov 10BenzingaHIMS
      Hims & Hers Drops 18% as Q3 Loss and Profit Outlook Cut Disappoint; Novo Nordisk Slides 2%, Eli Lilly Holds Steady
      Nov 10Yahoo FinanceHIMSLLYNVO
      Hims & Hers Drops 18% as Wall Street Loses Patience
      Nov 10Yahoo FinanceHIMS
      Hims & Hers Celebrated Its Eli Lilly Deal, Then Lost a Quarter of Its Value in a Week
      Nov 10Yahoo FinanceHIMSLLY
      Hims & Hers earnings analysis: questions answered and next catalysts
      Nov 10Investing.comHIMS
      Hims & Hers Health Inc (HIMS) (Q3 2026) Earnings Call Highlights: Revenue Surges 49% to ...
      Nov 10Yahoo FinanceHIMS
      HIMS May See Heightened ‘Gyrations’ As Weight-Loss Drug Trends Fuel Subscriber Uncertainty, Jefferies Warns – Stock Hits 7-Month Lows
      Nov 10Yahoo FinanceHIMS
      Hims & Hers Health slides 14% after earnings miss, guidance cut (HIMS:NYSE)

      Hims & Hers shares fall 14% after Q3 revenue of $890.3 million and EPS of -$0.14 miss estimates; 2026 revenue guidance narrows to $3.13B-$3.15B.

      Nov 10Seeking AlphaHIMS
      Hims & Hers stock sinks after Q3 results, outlook disappoints
      Nov 10Yahoo FinanceHIMS
      These Analysts Revise Their Forecasts On Hims & Hers Health After Q3 Results
      Nov 10BenzingaHIMS
      Hims & Hers cuts 2026 earnings outlook despite 49% revenue growth
      Nov 10Yahoo FinanceHIMS
      Hims & Hers Stock Plunges as Profit Vanishes and Growth Engine Sputters

      Hims & Hers Earnings Disaster as Costs Soar and Outlook Falls Far Short

      Nov 10Yahoo FinanceHIMS
      Hims & Hers Sinks 9% on EBITDA Guidance Cut as CEO Says He’d Take Subscriber Losses “Every Time”
      Nov 10Yahoo FinanceHIMS
      Hims & Hers Stock Plunges Despite 49% Revenue Surge

      Subscribers fell by 100,000 from the previous quarter, prompting concerns about near-term growth.

      Nov 10Yahoo FinanceHIMS
      Hims & Hers: Why I'm Not Buying Back Yet (Rating Downgrade) (NYSE:HIMS)

      Hims & Hers: 22.7x adjusted EBITDA looks costly with gross margin at 57.2%; a 233-million-share scenario implies 46% downside to $12.45. Click for more on HIMS stock.

      Nov 10Seeking AlphaHIMS
      Hims & Hers teases November launch of Peptides+ (HIMS:NYSE)

      Hims & Hers plans to launch Peptides+ offering later this month with glutathione, NAD, sermorelin, and B-12; BPC-157 and TB-500 await regulatory nod. Read more here.

      Nov 10Seeking AlphaHIMS

      This is the newest page. Registered accounts read further back.